Skip to content
Menu

Head-to-head comparison

Renlo Health vs StackMD

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #64Desk pick
Renlo Health

One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.

$199/mo (see conditions) sema · $269/mo (see conditions) tirz · Verified September 2026

Marked down on: A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom.

vs
Ranked #187
StackMD

StackMD is a New York telehealth platform (Medical 360 HC PLLC) selling compounded semaglutide and tirzepatide, both formulated with B12 and glycine, alongside NAD+, sermorelin and other longevity peptides.

$199 (see conditions) sema · $299 (see conditions) tirz · Verified August 2026

Marked down on: ⛔ Four different semaglutide figures across two pages in August 2026 — $125 and $125/month on the home page, $199 and $99/month on the product page — under a header that promises 'Transparent Pricing'

Renlo Health takes this head-to-head with the higher Desk Score, 80/100 (B−) against 69/100 (C) for StackMD. StackMD still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Renlo Health

80/100

B−

Overall

StackMD

69/100

C

Price transparency

82
48

State access

64
86

Molecule range

72
66

Onboarding speed

92
80

Support responsiveness

90
74

Licensing & trust

88
70

The spec sheet

FieldRenlo HealthStackMD
Semaglutide$199/mosee conditions$199/mo (compounded, billed monthly at every dose)$199see conditions$199 on the product page (the home card says $125 and the same page's own block says $99/mo; no billing cycle stated at checkout, compounded)
Tirzepatide$269/mosee conditions$269/mo (compounded, billed monthly at every dose)$299see conditions$299 on the product page (the home card says $199; no billing cycle stated at checkout, compounded)
CoverageNot listed on Renlo Health's site (checked September 2026)All 50 states
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyInjectable only
Best forSomeone who wants a flat monthly bill, a named prescriber and a refund route, and can ignore an anchor nobody explains.A patient who has already chosen StackMD for another reason and is prepared to discover the real charge at checkout — not for anyone shopping on price.
Desk Score80/100B−69/100C

The verdict

Desk pick — Renlo Health

Renlo Health takes this head-to-head with the higher Desk Score, 80/100 (B−) against 69/100 (C) for StackMD. StackMD still holds its ground where its strengths line up with yours.

Choose Renlo Health if…

Someone who wants a flat monthly bill, a named prescriber and a refund route, and can ignore an anchor nobody explains.

$199/mo (see conditions) sema · $269/mo (see conditions) tirz

Choose StackMD if…

A patient who has already chosen StackMD for another reason and is prepared to discover the real charge at checkout — not for anyone shopping on price.

$199 (see conditions) sema · $299 (see conditions) tirz · All 50 states

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Renlo Health · StackMD.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.